Seroepidemiological studies showed that the human polyomavirus KI (KIPyV) is common in the human population, with age-specific seroprevalence ranging from 40-90 %. Genome epidemiological analyses demonstrated that KIPyV DNA is predominantly found in respiratory tract samples of immunocompromised individuals and children suffering from respiratory diseases, but viral sequences have also been detected in brain, tonsil, lymphoid tissue studies, plasma, blood and faeces. Little is known about the sequence variation in the non-coding control region of KIPyV variants residing in different sites of the human body and whether specific strains dominate in certain parts of the world. In this study, we sequenced the non-coding control region (NCCR) of naturally occurring KIPyV variants in nasopharyngeal samples from patients with respiratory symptoms or infection and in blood from healthy donors in Norway. In total 86 sequences were obtained, 44 of which were identical to the original isolated Stockholm 60 variant. The remaining NCCRs contained one or several mutations, none of them previously reported. The same mutations were detected in NCCRs amplified from blood and nasopharyngeal samples. Some patients had different variants in their specimens. Transient transfection studies in HEK293 cells with a luciferase reporter plasmid demonstrated that some single mutations had a significant effect on the relative early and late promoter strength compared with the Stockholm 60 promoter. The effect of the NCCR mutations on viral replication and possible virulence properties remains to be established.
INTRODUCTION
Polyomaviruses are non-enveloped viruses with a circular dsDNA genome of approximately 5000 bp. These viruses are common in birds and mammals, and recently the first complete fish polyomavirus genome has been published (Johne et al., 2011; Peretti et al., 2015) . Their genome can †These authors contributed equally to this work.
be divided into three functional regions: the early region, encoding regulatory proteins required for transcription and viral DNA replication; the late region, encoding the capsid proteins; and interspersed between these the non-coding control region (NCCR), encompassing the origin of replication and the promoters controlling transcription of the early and late genes, respectively (DeCaprio & Garcea, 2013) . The first human polyomaviruses, BK and JC, were detected using histology or cytology followed by electron microscopy, and their existence was reported in 1971 (Gardner et al., 1971; Padgett et al., 1971) . The development of new techniques such as high-throughput sequencing, rolling circle amplification and polymerase chain reaction with degenerate primers has led in recent years to the discovery of new polyomaviruses that can infect humans. KI polyomavirus, named after the researchers' institute (Karolinska Institute) was the first novel human polyomavirus to be characterized, in 2007 (Allander et al., 2007) . Since then, 10 additional human polyomaviruses have been identified: WUPyV, Merkel cell polyomavirus, human polyomaviruses (HPyVs) 6, 7, 9, 10 and 12, Trichodysplasia spinulosa-associated polyomavirus, STL-PyV (and the isolates MW and MX) and NJPyV-2013 (Gaynor et al., 2007; Feng et al., 2008; Schowalter et al., 2010; van der Meijden et al., 2010; Scuda et al., 2011; Buck et al., 2012; Siebrasse et al., 2012; Yu et al., 2012; Korup et al., 2013; Lim et al., 2013; Mishra et al., 2014) .
Human polyomavirus KI (KIPyV) was originally isolated from 20 pooled nasopharyngeal aspirates (Allander et al., 2007) . Seroepidemiological studies revealed that KIPyV infection is common in the human population, with seroprevalence >50 % in the adult age group (Kean et al., 2009; Nguyen et al., 2009; Kantola et al., 2010; Neske et al., 2010; Gossai et al., 2016) . Primary infection seems to occur in early childhood, as KIPyV DNA can be detected in respiratory specimens from children <6 months old (Bialasiewicz et al., 2007 (Bialasiewicz et al., , 2008 Abedi Kiasari et al., 2008; Ren et al., 2008; Wattier et al., 2008) . Little is known about the cell tropism of this virus, but viral sequences are predominantly found in respiratory tract secretions, with prevalence ranging between 0.5 and 6.5 % (Babakir-Mina et al., 2013) . KIPyV DNA has occasionally been amplified from paranasal tissue (Babakir-Mina et al., 2009b) , tonsil (Babakir-Mina et al., 2009b; Astegiano et al., 2010) , lymphoid tissue (Sharp et al., 2009) , lung tissue (Babakir-Mina et al., 2009c; Teramoto et al., 2011) , stool (Allander et al., 2007; Babakir-Mina et al., 2009a; Bialasiewicz et al., 2009; Kantola et al., 2009; Mourez et al., 2009; Li et al., 2013) , brain (Barzon et al., 2009b) , eyebrow hair (Hampras et al., 2015) , normal skin (Hampras et al., 2015) and blood and plasma (Barzon et al., 2009a; Babakir-Mina et al., 2010; Csoma et al., 2012; Touinssi et al., 2013) . Immunohistochemical assay of spleen tissue from a 42-year-old human immunodeficiency virus (HIV)-positive male with a monoclonal antibody against the capsid protein VP1 of KIPyV stained positive, but the identity of the KIPyV VP1-positive cell type could not be determined (Siebrasse et al., 2014) .
Little information is available on genome sequence variability of circulating KIPyV strains in different biological specimens. Moreover, how genome polymorphism may affect viral activity remains unknown. To date, the complete genome sequences of 10 KIPyV strains have been deposited in GenBank (Stockholm variants 60, 350, 380; Brisbane variants 001, 002, 003; FZ52 and HN057) , and the NCCRs of three additional isolates (Brisbane variants 004, 006 and 007) are also available. The KIPyV isolates are derived from Sweden, Australia, China and Thailand, and their NCCR sequences contain minor differences (Tables 1 and S1 , the latter available in the online Supplementary Material). The effect of mutations on the transcriptional activity of KIPyV early and late promoters has not been examined. In this study, we investigated whether KIPyV strains with different NCCRs are circulating in the Norwegian population and whether polymorphisms in the NCCR affect early and late promoter activity.
RESULTS

KIPyV detection in nasopharyngeal samples and blood
Nasopharyngeal samples (n=94) from individuals with respiratory symptoms or infection and blood samples (n=96) from healthy blood donors were examined for the presence of KIPyV DNA using previously published primers that amplify part of the VP1 gene (Allander et al., 2007) . Each sample was tested three times and a sample was considered positive when a minimum of two out of three PCRs gave a positive product. Amplified KIPyV VP1 DNA was obtained for 10 (10.6 %) of the nasopharyngeal samples and for 12 (12.5 %) of the blood samples.
Next, we wanted to determine whether mutations occurred in the NCCR and whether unique NCCRs were associated with clinical conditions. For this, the complete NCCR was amplified from KIPyV DNA-positive samples. To analyse whether several KIPyV genome variants were present in the same sample extract, PCR products were cloned and three to six colonies per cloning were sequenced. In total, 86 readable sequences were obtained from 22 subjects (12 patients suffering from respiratory tract disease or infection and 10 blood donors). Forty-four (51 %) of the NCCR sequences were completely identical to the NCCR of the previously described Stockholm 60 (EF127906) strain (Allander et al., 2007) . Sequence analysis showed that 15 out of 38 (39.5 %) isolates from blood specimens contained mutations, while 27 out of 48 (56.3 %) isolates from nasopharyngeal samples carried mutations. The sequence of the Stockholm 60 NCCR is given in Fig. S1 . The NCCR of this variant is identical to the NCCR of Brisbane 002, Brisbane 004, Brisbane 006, Brisbane 007 and CU-258 (Table S1 ) (Bialasiewicz et al., 2007 (Bialasiewicz et al., , 2009 Payungporn et al., 2008) . Because Stockholm 60 NCCR was most frequently detected in our biological samples and is also detected in other parts of the world, (Moens et al., 2015) using the same PCR conditions as applied for the nasopharyngeal and blood samples. The amplicon was cloned and six colonies were sequenced. All sequences were identical to the Stockholm 60 sequence, suggesting that the PCR and cloning had not introduced unwanted mutations.
Effect of mutations on early and late promoter activity
The host tropism of KIPyV is not known, and cell culture models sustaining viral replication are lacking. We have previously investigated the early and late promoter activities of all 13 known human polyomaviruses in 10 different cell lines and found that the KIPyV early and late promoters had highest activity in the human embryonic kidney cell line HEK293 (Moens et al., 2015) . These cells were therefore used to compare the relative promoter strength of the mutant NCCRs to the Stockholm 60 NCCR. We decided to test the effect of single mutations on the relative promoter activity because this may allow us to correlate this particular mutation with changed promoter strength. Analysing the effect of multiple mutations on promoter strength does not allow us to pinpoint which mutation(s) contribute(s) to altered activity. Eighteen of 24 isolates containing a single nucleotide substitution were selected and their early and late promoter activities were compared to those of Stockholm 60. These NCCR variants were primarily selected because the ALGGEN PROMO algorithm (Messeguer et al., 2002; Farre et al., 2003) predicts that the mutations affect putative transcription factor binding sites (Table S3 ). Investigating single mutations allowed us to speculate on the biological importance of the putative binding sites for transcription factors for the viral promoter activity.
Mutations in early and late Bld29d, Bld38d, Bld69c, NPA1a and NPA7b promoters, and in early Bld62c and NPA74c promoters, did not significantly alter the strength compared with the corresponding promoter of Stockholm 60 (Fig. 2) . Mutations in NCCR variants Bld22c, Bld45d and Bld71c resulted in a reproducible tendency towards reduced early and late activity. A significant (P<0.0002) reduction was observed for the NPA89d and NPA44a early and late promoters, the Bld38c and Bld60c early promoters, and the NPA57a and NPA74c late promoters. A significant increase was measured for the early and late NPA7d and Bld60d (P<0.001) promoters. Most mutations resulted in an increase or decrease of both the early and late promoter activity, but the differences were not statistically significant. Exceptions were the NCCR variants Bld38c (C85T) and NPA94a (T189C), where the early promoter activity decreased and the late promoter activity increased compared with the Stockholm 60 NCCR. The opposite was observed for the Bld29d (A33G) promoter: the early promoter was up to 30 % stronger than the early Stockholm 60 promoter (P=0.04), while the late promoter was up to 25 % weaker than the late Stockholm 60 promoter (P=0.0007).
To link the changes in promoter activity to altered transcription factor binding sites, we tested the NPA7d NCCR. The NPA7d NCCR has one point mutation with a c-Myb binding site removed compared with Stockholm 60. c-Myb can act as a transcriptional repressor and activator (Nakagoshi et al., 1989); hence removal of a c-Myb motif may explain the increased NPA7d promoter activity compared with Stockholm. Co-transfection with a c-Myb expression plasmid showed that the early promoter of Stockholm 60 was stimulated 2.3-fold (P<0.001), while the early NPA7d activity increased 1.9-fold (P<0.001). The late promoter of Stockholm was stimulated 2.4-fold (P<0.001) and the late NPA7d promoter 2.1-fold (P=0.0011) by c-Myb. There was no significant difference in c-Myb-induced activation of the Stockholm 60 and NPA7d promoters (P>0.06; Fig. 3 ).
Comparison of the relative Stockholm 60 and Brisbane 001 promoter strength in HEK293 cells
The NCCRs of Brisbane 001, Brisbane 005 and CU-255 contain the 10 bp insertion AGGCGCTGCG between nucleotides A132 and G133, and three additional point mutations (T180C, T183A, C306A) compared with Stockholm 60 (Tables 1 and S1 ) (Bialasiewicz et al., 2007 (Bialasiewicz et al., , 2009 Payungporn et al., 2008) . All three variants were isolated from nasopharyngeal samples (Bialasiewicz et al., 2007 (Bialasiewicz et al., , 2009 Payungporn et al., 2008) . Because of the 10 bp insertion unique to these isolates, we decided to compare the relative strength of the Brisbane 001 early and late promoters to Stockholm 60 in HEK293 cells. Both the early and late promoters of Brisbane 001 were significantly (P<0.001) stronger than the corresponding promoters of Stockholm 60 (Fig. 4) . The early Brisbane 001 promoter was on average 1.8-fold stronger, while the late promoter was 1.3-fold stronger than the corresponding Stockholm 60 promoter.
DISCUSSION
PCR-based studies on respiratory tract samples collected from different patient groups of all ages and from different parts of the world showed a KIPyV DNA prevalence ranging from 0.5 to 12.1 % (Babakir-Mina et al., 2013; Iaria et al., 2015) . On the other hand, longitudinal studies on nasal swabs from 56 healthy children in Australia during their first 18 months of life and on haematopoietic stem cell recipients showed that 45 % of the healthy children and 26 % of the transplant patients had 1 KIPyV DNA-positive sample (Kuypers et al., 2012; Rockett et al., 2015) . KIPyV DNA has been detected in blood or plasma from healthy individuals, wheezing children, HIV-positive patients, haematopoietic stem cell or renal transplant patients, and tonsillectomy patients, with a frequency of 0- Fig. 2 . Effect of single point mutations on the relative early and late promoter activity of KIPyV. HEK293 cells were transfected with a luciferase reporter plasmid containing the early or the late promoter of KIPyV variants isolated from blood (Bld) or nasopharyngeal samples (NPA). Luciferase values were corrected for the protein content in each sample. The early or late promoter activity of the Stockholm 60 strain was arbitrarily set as 100 % and the promoter activities of the variants were related to this. Each experiment was repeated three to five times, each time with three independent parallels for every experiment. The results are presented as box plots. The box plots of the Stockholm 60 early and late promoters are shown on the right side of the figure. The red line represents the 100 % activity of KIPyV Stockholm 60 early (respectively late) promoter. The blue box plots denote the early promoter activity, the green plots late promoter activity. The asterisk is a far outlier that showed a >1.5-fold higher (respectively lower) value than the upper (respectively lower) quartile, while the open dots are outliers that displayed a <1.5-fold higher (respectively lower) value than the upper (respectively lower) quartile.
Mina et al., 2013). We found that 10.6 % of the nasopharyngeal samples (n=94) taken from patients with respiratory symptoms or infection contained KIPyV DNA and 12.5 % (n=96) of the blood specimens from healthy individuals were positive for VP1 DNA. These prevalences are higher than found by other groups, but this could be due to the patient group examined. Upper respiratory infections may predispose the host to higher susceptibility for KIPyV infection or reactivation. The use of different viral DNA extraction methods, primers and PCR conditions, geographical differences, and age of the subjects may also affect the genoprevalence.
About 50 % of the NCCR sequences from our samples were identical to the NCCR of Stockholm 60, suggesting that this strain may represent the archetypal strain. This is underscored by the finding of KIPyV with Stockholm 60 NCCR in individuals from Australia, Thailand and China (Table S1 ). Fifty-seven per cent of the non-Stockholm 60 NCCRs possessed single nucleotide substitutions, while 43 % had two or more point mutations. None of the mutations identified in this cohort was reported in other studies, while previously reported mutations were not found here, in the NCCR sequences from nasopharyngeal and blood samples of Norwegian individuals. This may suggest that specific variants may circulate in different geographical regions. However, additional sequences must be obtained to demonstrate a possible geographical distribution of KIPyV subtypes. The higher number of isolates carrying mutations from nasopharyngeal samples compared with isolates from blood (56.3 vs 39.5 %) may suggest a higher mutation rate in the former. However, more isolates from different sources need to be sequenced to confirm this. Of those mutations that occurred in several variants, G188A and G484A were exclusively detected in NCCRs amplified from nasopharyngeal samples, suggesting that these mutations may be specific for KIPyV circulating in the respiratory system. Viruses with different NCCRs were detected in the same sample of a particular patient, underscoring that viral replication may have occurred. Indeed, PyV replication leads to mutations in the NCCR (Imperiale & Jiang, 2015) . However, the genuine host cell(s) for KIPyV remain(s) to be identified and transcription factors involved in early and late transcription have not been characterized. To explore the impact of NCCR polymorphisms on promoter activity, we initiated studies with some of the NCCRs carrying a single mutation. Most mutations altered the strength of the viral promoter activity, but the effect of the mutations reported in this study on binding of transcription factors can only be speculated. Using the ALGGEN-PROMO algorithm (Messeguer et al., 2002; Farre et al., 2003) , we examined the effect of mutations on the putative transcription factor binding sites. Most point mutations removed or introduced multiple possible binding sites. However, the mutations A57G (NPA7b), A166G (NPA7d), C208T (Bld62c), G291A (Bld71c) and G484A (NPA1a) removed a single putative site for Pu-box binding factor, c-Myb, E2F- 1, AP2aA and GATA-2 site, respectively. The T154C substitution (NPA74c) generated a putative Pax5 binding site (Table S3) . Co-transfection studies with a c-Myb expression plasmid showed that both the early and late NPA7a promoters were still activated, with levels similar to the Stockholm 60 early and late promoters. The increased activity of the early and late promoters of NPA7d compared with Stockholm 60 does not seem to be the result of removal of a putative c-Myb site. These observations indicate that, despite the usefulness of transcription factor site algorithms, experimental studies are absolutely required to confirm the functionality of a putative binding site.
The large T-antigen is also required for transcription, and binds the consensus sequence 5¢-GAGGC-3¢ . Putative large T-antigen binding motifs are present at positions 4-8, 14-18, 25-29, 73-77 and 80-84 in the Stockholm 60 NCCR. The mutations C8A (NPA94b), T28C (NPA7a, Bld29b, Bld60c), C74T (Bld22d) and C77T (NPA1c) may thus abrogate large T-antigen binding. We only tested NCCR variant Bld60c, which displayed decreased early and late promoter activity compared with Stockholm 60 (Fig. 2) . Because the experiments were performed in the absence of large T-antigen, diminution in Bld60c promoter activity cannot be attributed to reduced large T-antigen binding.
We also compared the promoter activities of Stockholm 60 and Brisbane 001. The latter has a 10 bp insertion and three point mutations compared with Stockholm 60. The 10 bp insertion does not contain any putative transcription factor binding sites based on the ALGGEN PROMO algorithm, but sites for AP2-a and HNF4/LF-A1 are created at the borders of the insertion (Messeguer et al., 2002; Farre et al., 2003) . AP2-a binds the SV40 promoter, but large T-antigen prevents this interaction by directly binding AP2-a (Mitchell et al., 1987) . Interestingly, AP2-a is highly expressed in oral mucosa, tonsils and oesophagus, and also in the kidneys and female reproductive system and the skin (Uhlen et al., 2010) . HNF4 expression is restricted to the digestive tract, kidneys, testes, skin and heart muscle, but seems absent in oral mucosa, salivary glands, oesophagus, tonsils and the respiratory system (Uhlen et al., 2010) . The point mutations created a putative site for the testis-specific SRY transcription factor. To the best of our knowledge, the prevalence of KIPyV in testis has not been examined, except for one patient whose testes were negative for VP1 protein (Siebrasse et al., 2014) . Because we monitored the promoter activities of Stockholm 60 and Brisbane 001 in kidney cells, the additional AP2-a site in the Brisbane 001 NCCR may explain its higher activity compared with Stockholm 60.
In conclusion, our results demonstrate that Stockholm 60 is the most prevalent KIPyV strain in our nasopharyngeal and blood samples and that point mutations are present in strains circulating in the human population. However, larger rearrangements as seen for the BKPyV and JCPyV promoters seem to be rare. The absence of a cell culture system that sustains replication of KIPyV and the lack of association of KIPyV with disease does not allow conclusions on the effect of these NCCR variants on viral replication and virulence.
METHODS
Clinical samples. Blood samples (n=96) were collected from healthy blood donors, while 94 nasopharyngeal samples were obtained from patients with respiratory symptoms or infection. This study was approved by the Ethics Committee of the University of Tromsø (REK2012/410). Viral DNA was extracted from nasopharyngeal samples by means of the QIAamp MinElute Virus Spin kit (Qiagen), while DNA from whole blood was isolated by the use of an automated DNA extractor GenoVision M48 (QIAGEN).
PCR and cloning. Nasopharyngeal and blood samples were originally screened for the presence of KIPyV DNA using the primers 5¢-CGCAG-TACCACTGTCAGAAGAAC-3¢ and 5¢-TTCTGCCAGGCTGTAACA-TAC-3¢, amplifying a fragment of the VP1 gene (Allander et al., 2007) . KIPyV NCCR was amplified from VP1-positive samples using the primer set 5'-CGCAGTACCACTGTCAGAAGAAAC-3' and 5'-AGATCTCTAAAAACAAAATAAAAATTGGTGACCCT-3'. PCR conditions were 5 min at 95 C, followed by 40 cycles of 30 s at 95 C, 1 min at 54 C, and 1 min at 72 C. A final extension step of 10 min at 72 C was included. The AccuPrimeTaq DNA Polymerase, High Fidelity with 3'-5' exonuclease activity (proofreading) was used (ThermoFisher Scientific). The PCR products were cloned and transformed in competent E. coli DH5 cells. After transformation, several colonies were select, and plasmid DNA was purified (NucleoSpin Plasmid; Machery-Nagel) and sequenced. Cycle sequencing reactions were performed using the BigDye 3.1 Sequencing kit (Life Technologies). HEK293 cells were transfected with a luciferase reporter containing the early or late promoter of Stockholm 60 (respectively Brisbane 001). The relative promoter activities were calculated as described in the legend of Fig. 1 . The experiment was repeated three or four times with three independent parallels for each experiment. The results are presented as box plots. There was a significant difference (P<0.001) between the early (respectively late) promoter activity of Stockholm 60 and Brisbane 001.
have been previously described (Moens et al., 2015) . These plasmids were used to introduce single nucleotide substitutions using the primers given in Table S2 . The reporter plasmids with the Brisbane 001 early or late promoter were generated by site-directed mutagenesis of the aforementioned plasmids by first using a primer set that resulted in addition of 10 bp. Subsequently, two additional site-directed mutagenesis reactions were performed to introduce the point mutations for the sequences of the site-directed mutagenesis primers in Table S2 . All mutations were verified by sequencing. The human c-Myc expression plasmid was a kind gift from Odd Stokke Gabrielsen (Molvaersmyr et al., 2010) .
Cells. HEK293 cells were maintained in Dulbecco's Modified Eagle's Medium (Sigma) with 10 % FBS (Life Technologies).
Transfection. Cells were seeded out in 12-well cell culture plates and transfected the following day. Cells were approximately 70-85 % confluent on the day of transfection. JetPrime (Polyplus) was used as transfection reagent according to the manufacturer's protocol. Each transfection was repeated three to five times with three independent parallels each.
Luciferase assays. Cells were lysed approximately 24 h post-transfection in 100 µl Luciferase Assay Tropix Lysis solution with 0.5 mM DTT freshly added. Cells were scraped and transferred to Eppendorf tubes, followed by 3 min centrifugation at 12 000 g. Supernatant (20 µl) was transferred to 96-well microtitre plates and luciferase buffer (Promega) was added. Light units were measured in a luminometer (Labsystem Luminoscan RT). The activity of the early and late Stockholm 60 promoter was arbitrarily set as 100, and the activity of the promoters of the other variants was related to this. Luciferase values were adjusted for the protein concentration in each sample. The protein concentration was measured using the Protein Quantification Assay from Macherey-Nagel.
Statistical analysis. The t-test was employed to determine statistical differences between the Stockholm 60 and mutant promoters.
